- Home
- PHAT vs HSDT Comparison
PHAT vs HSDT Comparison
Compare PHAT & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- HSDT
- Stock Information
- Founded
- PHAT 2018
- HSDT N/A
- Country
- PHAT United States
- HSDT United States
- Employees
- PHAT N/A
- HSDT N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PHAT Health Care
- HSDT Health Care
- Exchange
- PHAT Nasdaq
- HSDT Nasdaq
- Market Cap
- PHAT 769.0M
- HSDT 707.6M
- IPO Year
- PHAT 2019
- HSDT N/A
- Fundamental
- Price
- PHAT $11.70
- HSDT $16.78
- Analyst Decision
- PHAT Strong Buy
- HSDT Hold
- Analyst Count
- PHAT 5
- HSDT 1
- Target Price
- PHAT $16.40
- HSDT N/A
- AVG Volume (30 Days)
- PHAT 1.3M
- HSDT 1.9M
- Earning Date
- PHAT 11-06-2025
- HSDT 11-11-2025
- Dividend Yield
- PHAT N/A
- HSDT N/A
- EPS Growth
- PHAT N/A
- HSDT N/A
- EPS
- PHAT N/A
- HSDT N/A
- Revenue
- PHAT $114,039,000.00
- HSDT $295,000.00
- Revenue This Year
- PHAT $213.11
- HSDT N/A
- Revenue Next Year
- PHAT $91.84
- HSDT $75.13
- P/E Ratio
- PHAT N/A
- HSDT N/A
- Revenue Growth
- PHAT 1049.82
- HSDT N/A
- 52 Week Low
- PHAT $2.21
- HSDT $5.37
- 52 Week High
- PHAT $19.50
- HSDT $1,200.00
- Technical
- Relative Strength Index (RSI)
- PHAT 50.37
- HSDT 58.69
- Support Level
- PHAT $10.33
- HSDT $12.50
- Resistance Level
- PHAT $12.97
- HSDT $20.50
- Average True Range (ATR)
- PHAT 0.89
- HSDT 2.19
- MACD
- PHAT -0.11
- HSDT -0.18
- Stochastic Oscillator
- PHAT 45.41
- HSDT 45.59
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.